Verzenio (abemaciclib) — Medica
Recurrent or metastatic breast cancer in men, HR+ disease
Initial criteria
- age ≥ 18 years
- recurrent or metastatic breast cancer
- HR+ disease
- EITHER HER2-negative breast cancer AND ONE of:
- • receiving a GnRH analog AND used in combination with anastrozole, exemestane, or letrozole; OR
- • used in combination with fulvestrant; OR
- • used as monotherapy after progression on at least one prior endocrine therapy AND after chemotherapy for metastatic disease
- OR HER2-positive breast cancer AND BOTH:
- • at least three prior anti-HER2-based regimens in metastatic setting; AND
- • used in combination with fulvestrant and trastuzumab
Approval duration
1 year